BR112020013716A2 - Peptídeos terapêuticos e métodos para tratar doença autoimune relacionada - Google Patents
Peptídeos terapêuticos e métodos para tratar doença autoimune relacionada Download PDFInfo
- Publication number
- BR112020013716A2 BR112020013716A2 BR112020013716-2A BR112020013716A BR112020013716A2 BR 112020013716 A2 BR112020013716 A2 BR 112020013716A2 BR 112020013716 A BR112020013716 A BR 112020013716A BR 112020013716 A2 BR112020013716 A2 BR 112020013716A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- peptide
- cells
- fact
- protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 596
- 238000000034 method Methods 0.000 title claims abstract description 279
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 108
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 338
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 114
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 102
- 206010061218 Inflammation Diseases 0.000 claims abstract description 91
- 230000004054 inflammatory process Effects 0.000 claims abstract description 91
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 89
- 230000001363 autoimmune Effects 0.000 claims abstract description 33
- 230000009467 reduction Effects 0.000 claims abstract description 22
- 208000011594 Autoinflammatory disease Diseases 0.000 claims abstract description 12
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims abstract description 6
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 claims abstract description 6
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 395
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 395
- 102100032937 CD40 ligand Human genes 0.000 claims description 198
- 230000003993 interaction Effects 0.000 claims description 157
- 230000027455 binding Effects 0.000 claims description 87
- 206010012601 diabetes mellitus Diseases 0.000 claims description 67
- 241001465754 Metazoa Species 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 34
- 230000002441 reversible effect Effects 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 23
- 108090000695 Cytokines Proteins 0.000 claims description 23
- 102000013691 Interleukin-17 Human genes 0.000 claims description 22
- 108050003558 Interleukin-17 Proteins 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 21
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 20
- 238000001990 intravenous administration Methods 0.000 claims description 18
- 230000001419 dependent effect Effects 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 13
- 102000000588 Interleukin-2 Human genes 0.000 claims description 13
- 208000037976 chronic inflammation Diseases 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 230000006020 chronic inflammation Effects 0.000 claims description 12
- 238000007918 intramuscular administration Methods 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 208000026872 Addison Disease Diseases 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 10
- 239000007943 implant Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- -1 splenic CD4hi cells Proteins 0.000 claims description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 8
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 8
- 108010029697 CD40 Ligand Proteins 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 8
- 208000027868 Paget disease Diseases 0.000 claims description 8
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 8
- 206010047115 Vasculitis Diseases 0.000 claims description 8
- 206010069351 acute lung injury Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 208000027202 mammary Paget disease Diseases 0.000 claims description 8
- 206010043778 thyroiditis Diseases 0.000 claims description 8
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 7
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 7
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 238000003304 gavage Methods 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011859 microparticle Substances 0.000 claims description 5
- 239000004005 microsphere Substances 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 239000002077 nanosphere Substances 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 claims description 4
- 108091006300 SLC2A4 Proteins 0.000 claims description 4
- 230000003393 splenic effect Effects 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 10
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 18
- 230000007423 decrease Effects 0.000 abstract description 13
- 230000002452 interceptive effect Effects 0.000 abstract description 11
- 230000028709 inflammatory response Effects 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 7
- 238000011161 development Methods 0.000 description 115
- 230000018109 developmental process Effects 0.000 description 115
- 150000001413 amino acids Chemical class 0.000 description 86
- 241000699670 Mus sp. Species 0.000 description 85
- 230000002757 inflammatory effect Effects 0.000 description 49
- 235000001014 amino acid Nutrition 0.000 description 47
- 238000003556 assay Methods 0.000 description 46
- 238000012360 testing method Methods 0.000 description 46
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 201000010099 disease Diseases 0.000 description 33
- 239000003550 marker Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 29
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 26
- 102100029470 Apolipoprotein E Human genes 0.000 description 23
- 101710095339 Apolipoprotein E Proteins 0.000 description 23
- 230000004913 activation Effects 0.000 description 23
- 102000004877 Insulin Human genes 0.000 description 22
- 108090001061 Insulin Proteins 0.000 description 22
- 229940125396 insulin Drugs 0.000 description 22
- 230000004957 immunoregulator effect Effects 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 210000002865 immune cell Anatomy 0.000 description 18
- 210000002540 macrophage Anatomy 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 15
- 206010022489 Insulin Resistance Diseases 0.000 description 15
- 210000002376 aorta thoracic Anatomy 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 14
- 201000001421 hyperglycemia Diseases 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 210000000496 pancreas Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 210000000709 aorta Anatomy 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 230000003143 atherosclerotic effect Effects 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 208000038016 acute inflammation Diseases 0.000 description 9
- 230000006022 acute inflammation Effects 0.000 description 9
- 230000005784 autoimmunity Effects 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 102000008070 Interferon-gamma Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102100030704 Interleukin-21 Human genes 0.000 description 6
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 210000003651 basophil Anatomy 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 108010074108 interleukin-21 Proteins 0.000 description 6
- 108010074109 interleukin-22 Proteins 0.000 description 6
- 229940028885 interleukin-4 Drugs 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 229940044627 gamma-interferon Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 229940076144 interleukin-10 Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 208000023328 Basedow disease Diseases 0.000 description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 4
- 208000015023 Graves' disease Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 241000976416 Isatis tinctoria subsp. canescens Species 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 108010034143 Inflammasomes Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 102000001183 RAG-1 Human genes 0.000 description 3
- 108060006897 RAG1 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000007214 atherothrombosis Effects 0.000 description 2
- 201000004983 autoimmune atherosclerosis Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002168 brachiocephalic trunk Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000012085 chronic inflammatory response Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000000893 fibroproliferative effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000011773 genetically engineered mouse model Methods 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- 108060000255 AIM2 Proteins 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 1
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
- 101100228210 Caenorhabditis elegans gly-7 gene Proteins 0.000 description 1
- 101100335897 Caenorhabditis elegans gly-9 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 101100346152 Drosophila melanogaster modSP gene Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 101150013552 LDLR gene Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614262P | 2018-01-05 | 2018-01-05 | |
| US62/614,262 | 2018-01-05 | ||
| US16/184,129 | 2018-11-08 | ||
| US16/184,129 US20190194290A1 (en) | 2010-10-19 | 2018-11-08 | Methods for preventing, modulating and/or reducing cardiovascular disease |
| PCT/US2019/012425 WO2019136307A1 (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020013716A2 true BR112020013716A2 (pt) | 2020-12-22 |
Family
ID=67144298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020013716-2A BR112020013716A2 (pt) | 2018-01-05 | 2019-01-04 | Peptídeos terapêuticos e métodos para tratar doença autoimune relacionada |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3735260B1 (https=) |
| JP (2) | JP7511242B2 (https=) |
| CN (2) | CN119157997A (https=) |
| AU (1) | AU2019205328B2 (https=) |
| BR (1) | BR112020013716A2 (https=) |
| CA (1) | CA3086193A1 (https=) |
| MX (1) | MX2020007081A (https=) |
| SG (1) | SG11202006494VA (https=) |
| WO (1) | WO2019136307A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| ES2957957T3 (es) | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| JP2022540731A (ja) * | 2019-07-12 | 2022-09-16 | オーピー－ティー エルエルシー | ペプチドおよび疾患の治療方法 |
| EP4135742A2 (en) * | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
| WO2021231898A2 (en) * | 2020-05-14 | 2021-11-18 | Op-T Llc | Nanoparticle compositions and uses thereof |
| WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CN115807071B (zh) * | 2022-09-02 | 2025-09-26 | 宁夏医科大学 | 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| WO2005006949A2 (en) * | 2003-07-07 | 2005-01-27 | Wagner David H | Methods for predicting development of auto-immune diseases and treatment of same |
| US7449200B2 (en) * | 2006-04-17 | 2008-11-11 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means |
| ES2957957T3 (es) * | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| JP6285923B2 (ja) * | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| EP3123176A4 (en) * | 2014-03-23 | 2018-04-25 | The Regents of the University of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
-
2019
- 2019-01-04 BR BR112020013716-2A patent/BR112020013716A2/pt unknown
- 2019-01-04 AU AU2019205328A patent/AU2019205328B2/en active Active
- 2019-01-04 JP JP2020557124A patent/JP7511242B2/ja active Active
- 2019-01-04 WO PCT/US2019/012425 patent/WO2019136307A1/en not_active Ceased
- 2019-01-04 CN CN202411324616.4A patent/CN119157997A/zh active Pending
- 2019-01-04 SG SG11202006494VA patent/SG11202006494VA/en unknown
- 2019-01-04 CN CN201980017176.9A patent/CN111801110B/zh active Active
- 2019-01-04 EP EP19736089.4A patent/EP3735260B1/en active Active
- 2019-01-04 CA CA3086193A patent/CA3086193A1/en active Pending
- 2019-01-04 MX MX2020007081A patent/MX2020007081A/es unknown
-
2024
- 2024-06-17 JP JP2024097199A patent/JP2024123100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020007081A (es) | 2020-10-28 |
| CN119157997A (zh) | 2024-12-20 |
| CN111801110B (zh) | 2024-10-18 |
| EP3735260B1 (en) | 2026-03-04 |
| WO2019136307A1 (en) | 2019-07-11 |
| AU2019205328B2 (en) | 2025-04-03 |
| EP3735260A1 (en) | 2020-11-11 |
| JP2021510174A (ja) | 2021-04-15 |
| SG11202006494VA (en) | 2020-08-28 |
| CN111801110A (zh) | 2020-10-20 |
| CA3086193A1 (en) | 2019-07-11 |
| JP7511242B2 (ja) | 2024-07-05 |
| EP3735260A4 (en) | 2021-12-08 |
| JP2024123100A (ja) | 2024-09-10 |
| AU2019205328A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020013716A2 (pt) | Peptídeos terapêuticos e métodos para tratar doença autoimune relacionada | |
| US8187596B1 (en) | Method of treating asthma or allergy by administering an IL-33 receptor antibody | |
| ES2677844T3 (es) | Péptidos para modular la actividad de linfocitos T y usos de los mismos | |
| US12428465B2 (en) | Therapeutic peptides and methods for treating type 2 diabetes | |
| JP2025116861A (ja) | ペプチドおよび疾患の治療方法 | |
| BRPI0718283A2 (pt) | Tratamento de distúrbios desmielinizantes | |
| Wang et al. | γ-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS | |
| US20200072837A1 (en) | Methods for preventing, modulating and/or reducing cardiovascular disease | |
| US20190194290A1 (en) | Methods for preventing, modulating and/or reducing cardiovascular disease | |
| ES3031007T3 (en) | Peptide for preventing, modulating and/or reducing cardiovascular disease | |
| US20040009174A1 (en) | Method of treating asthma | |
| WO2002046767A2 (en) | Diagnosis and treatment of alzheimer's disease | |
| US20060025335A1 (en) | Netrin compositions and methods of using the same | |
| US20230016187A1 (en) | Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease | |
| HK40095385A (en) | Peptides for modulating t-cell activity and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |